CD8A and non-small cell lung carcinoma: Analysis of scRNA-seq data from paired pre- and post-treatment tumor tissues in advanced NSCLC patients receiving chemotherapy plus pembrolizumab in the GSE179994 dataset confirmed a higher enrichment of memory and effector CD8 signatures in post-treatment tumor tissues, in line with our scRNA-seq results (Fig. 7a).